Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, Safety, and Immunogenicity of AVT03 vs Prolia in Healthy Males
NCT05126784Phase 1Completed
- Sponsor
- Alvotech
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DenOsteoRel in osteoporosis (2 arms), sponsored by Alvotech. Primary endpoints: Area under the serum concentration-time curve from day 0 to day 252, Area under the serum concentration-time curve from day 0 to infinity and 1 more. Started Jun 2022; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05126784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126784.